REUTERS: Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the entire class of drugs, including J&J's own approved Invokana treatment. Dominic Caruso, J&J's chief financial officer, on Tuesday gave his optimistic view of the new drug class, called SGLT2 inhibitors, during a conference call with industry analysts to discuss the company's third-quarter earnings.